🔎 Trials Near Me

Home › NCT07029581

Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis

RecruitingPhase 2

A Double-Blind, Placebo-Controlled, Phase 2, Efficacy and Safety Study of ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP)

Who can join

Ages 55 to 84 · All sexes

Full eligibility criteria
Inclusion Criteria:

* Male or female ≥55 years to \<85 years of age at the Screening visit living in the community or, if permitted by local regulations, in an institutionalized setting
* Can provide written informed consent. If the subject is deemed not competent to provide informed consent, the following requirements for consent must be met:

  1. The subject's LAR must provide written informed consent.
  2. The subject must provide written (if capable) informed assent per local regulations.
* Meets either the clinical criteria for Parkinson's disease with dementia as defined by the Movement Disorder Society's Task Force or the revised clinical criteria for probable dementia with Lewy bodies (DLB) by consensus criteria (Fourth consensus report of the DLB Consortium).
* Meets the revised criteria for psychosis in major or mild neurocognitive disorder established by the International Psychogeriatrics Association

Exclusion Criteria:

* Is in hospice, is receiving end-of-life palliative care, or is bedridden
* Has psychotic symptoms that are primarily attributable to delirium, substance abuse, or a medical or psychiatric condition (e.g. schizophrenia, bipolar disorder, delusional disorder) other than dementia
* Is actively suicidal at Visit 1 (Screening) or Visit 2 (Baseline)
* Has a history or current evidence of a serious and/or significant unstable cardiovascular, respiratory, endocrine, gastrointestinal, renal, hepatic, hematologic, immunologic, genitourinary, psychiatric or neurologic (including stroke, chronic seizures, or clinically significant head injury) abnormality or disease or other medical disorder, including cancer or malignancies that could interfere with subject's ability to complete the study or comply with study procedures
* Has other clinically significant CNS abnormalities that are most likely contributing to the dementia or findings on MRI or CT

About the study

Multicenter, randomized, 6-week, double-blind, placebo-controlled, parallel-group, Phase 2 study in subjects with LBDP.

What is being tested

Sponsor: ACADIA Pharmaceuticals Inc. · Participants: 180 · Started: Aug 6, 2025

Contact the study team

Official record on ClinicalTrials.gov — NCT07029581

Locations in the U.S.

CaliforniaATP Clinical Research Inc., Irvine
ColoradoThe University of Colorado, Aurora
District of ColumbiaGeorgetown University, Washington D.C.
FloridaHumanity Clinical Research, Corp, Aventura
Parkinson's Disease and Movement Disorders Center of Boca Raton, Boca Raton
K2 Medical Research Winter Garden LLC, Clermont
University of Florida - Shands, Gainesville
K2 Summit Research, Lady Lake
Advanced Clinical Research Network, Corp, Miami
Homestead Associates in Research Inc, Miami
MediClear Medical & Research Center, Inc., Miami
Premier Clinical Research Institute, Inc., Miami
Verus Clinical Research, Miami
Health Synergy Clinical Research, LLC, West Palm Beach
HawaiiHawaii Pacific Neuroscience, Honolulu
IllinoisRush University Medical Center, Chicago
KansasUniversity of Kansas Medical Center Research Institute Inc., Kansas City
New YorkParkinson's Disease and Movement Disorders Center of Boca Raton d/b/a Parkinson's Research Center of America-Long Island, Commack
North CarolinaUNC Hospitals, Chapel Hill
OhioCleveland Clinic Foundation, Cleveland
The Ohio State University, Energy Advancement and Innovation Center, Columbus
OklahomaThe Movement Disorder Clinic of Oklahoma, Tulsa
TexasHorizon Clinical Research Group, Cypress
Prolato Clinical Research Center, Houston
The University of Texas Health Science Center San Antonio, San Antonio
R and H Clinical Research, Stafford
VirginiaVirginia Commonwealth University (a public institution of higher education), Richmond
WashingtonEvergreenHealth, Kirkland

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.